A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
- Ocana, A.
- Gil-Martin, M.
- Martín, M.
- Rojo, F.
- Antolín, S.
- Guerrero, Á.
- Trigo, J.M.
- Muñoz, M.
- Pandiella, A.
- Diego, N.G.
- Bezares, S.
- Caballero, R.
- Carrasco, E.
- Urruticoechea, A.
ISSN: 1949-2553
Année de publication: 2017
Volumen: 8
Número: 42
Pages: 73144-73153
Type: Article